Advertisement
U.S. markets open in 2 hours 47 minutes

HilleVax, Inc. (HLVX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.62-0.22 (-1.39%)
At close: 04:00PM EDT
15.62 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close15.84
Open16.19
Bid15.53 x 200
Ask15.76 x 100
Day's Range15.53 - 16.23
52 Week Range9.94 - 20.22
Volume63,054
Avg. Volume124,932
Market Cap776.326M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.04
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HLVX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HilleVax, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/27/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GuruFocus.com

    Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX)

    Aditya Kohli, a director at HilleVax Inc (NASDAQ:HLVX), has sold 18,000 shares of the company on March 20, 2024, according to a recent SEC filing.

  • GlobeNewswire

    HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

    Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023 BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023, highlighted recent

  • GlobeNewswire

    HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

    BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and th